<DOC>
	<DOCNO>NCT01111604</DOCNO>
	<brief_summary>The purpose study determine patient metastatic colorectal cancer live longer without cancer progressing treat standard chemotherapy , standard chemotherapy plus IMC-1121B , standard chemotherapy plus IMC-18F1 .</brief_summary>
	<brief_title>A Study IMC-1121B IMC-18F1 Colorectal Cancer</brief_title>
	<detailed_description>The purpose study evaluate progression-free survival ( PFS ) patient metastatic colorectal cancer treat 1 3 modify FOLFOX-6 ( folinic acid [ FA ] + fluorouracil [ 5-FU ] + oxaliplatin [ mFOLFOX-6 ] ) -based regimen , second-line therapy . During 2010 , identify shortage injectable folinic acid ( FA ) United States . Levo-folinic acid ( LFA ) allow substitute FA mFOLFOX-6 chemotherapy regimen circumstance FA available , facilitate continuity patient care .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Disease progression irinotecanbased firstline chemotherapy regimen ( ie FOLFIRI CAPIRI [ capecitabine + irinotecan ] , without bevacizumab ) Age ≥ 18 year Life expectancy ≥ 6 month ECOG PS ( Eastern Cooperative Oncology Group Performance Status ) 01 study entry Agrees adequate contraception study period 12 week last dose study medication Provided sign informed consent Has receive prior oxaliplatinbased chemotherapy locally advance unresectable metastatic CRC ( Prior oxaliplatinbased adjuvant chemotherapy allow last dose oxaliplatin administer &gt; 12 month prior randomization ) Has document and/or symptomatic brain leptomeningeal metastasis Has ongoing active infection , symptomatic poorly control cardiac arrhythmia , psychiatric illness/social situation , serious uncontrolled medical disorder On chronic nontopical corticosteroid treatment . A patient discontinuing treatment &gt; 3 month prior randomization eligible Has uncontrolled poorly control hypertension standard regimen antihypertensive therapy Has concurrent active malignancy . A patient previous history malignancy eligible , provide he/she disease free &gt; 3 year If female , pregnant ( confirm serum beta human chorionic gonadotropin [ βHCG ] test ) lactating Has receive prior autologous allogeneic organ tissue transplantation Has undergone major surgery within 28 day prior randomization Has serious nonhealing wound , ulcer , bone fracture within 28 day prior randomization Has elective plan major surgery perform course trial Has history inflammatory bowel disease require pharmacological and/or surgical intervention 12 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Colonic Neoplasms</keyword>
	<keyword>Rectal Neoplasms</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>